Company intelligence / Profile preview
ChemoCentryx
Mountain View, California, United States
- Ownership
- Public · CCXI
- Employees
- ~200
- Development stage
- Commercial
01
Overview
ChemoCentryx has successfully commercialized TAVNEOS (avacopan), the first approved orally administered inhibitor of the complement 5a receptor for treating severe active ANCA-associated vasculitis. The company was acquired by Amgen in October 2022 for $4 billion.
- Therapeutic areas
- OncologyImmunologyDermatologyNephrology
- Modalities
- Small moleculesOrally-administered therapies
- Industry
- Biotech
02
Drug pipeline
18 assets17 more assets in the full pipeline.
Request access →03
Partnerships
Vifor Pharma (Kidney Health Alliance)
04
Financials
- Market cap
- $569.8M
- Total revenue
- $0
- Enterprise value
- $568.6M
Beyond the preview
Go deeper on ChemoCentryx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChemoCentryx.